Subject Index  by unknown







Adenocarcinoma, S29, S33, S73






Advanced lung cancer, S64
Advanced/metastatic NSCLC, S78





















Biomarkers, S12, S41, S44








Brain metastases, S12, S59, S70, S73, S77,
S82, S91
BRCA1, S32, S38, S41, S56
BRGI, S29
Bronchial, S94










Carboplatin, S55, S79, S88
Carcinogenesis, S34, S35
Carcinoid, S11, S94








Chemoradiotherapy, S21, S22, S25, S60, S63
Chemotherapy, S11, S12, S16, S26, S55, S57,
















Compression mediastinal syndrome, S93
Computer assisted analysis, S49
Concomitant, S60
Concomitant chemoradiotherapy, S21
Concurrent chemoradiotherapy, S60, S88
Cone-beam CT, S90
Consolidation, S60









CT scan, S50, S52










Docetaxel, S41, S51, S58, S65, S67, S68, S69,
S77, S79, S82
Dosage, S43
Dose escalation, S88, S89
E
Early detection, S9, S38, S49
Early lung cancer, S15
Early stage, S17, S18, S56
Early-stage lung cancer, S17, S91




EGFR inhibitors, S26, S59
EGFR mutation, S59, S71
Elderly, S60, S64, S65, S80, S81, S87
Elderly lung cancer, S64





Epidermal growth factor receptor (EGFR), S27,
S30, S32, S35, S36, S42, S48, S71, S72,
S78, S94
Epidermal growth factor receptor-tyrosine




ERCC1, S62, S66, S85
Erlotinib, S26, S38, S59, S69, S70, S71, S78,
S80, S83
Esophageal tolerance, S88
Excision repair cross-complementation group 1
(ERCC1), S16, S42
Experience, S94












Gefitinib, S38, S42, S55, S58, S59, S69, S71,
S72, S76, S84
Gemcitabine, S41, S58, S65, S66, S67, S76
Gender, S62
Gender differences, S37
Journal of Thoracic Oncology • Volume 3, Number 4, Supplement 1, April 2008S104
Gene amplification, S10
Gene expression, S23, S24
Gene expression profiling, S24, S42





Head and neck cancer, S87
Hedgehog, S28
Histology, S27, S29
Histone deacetylase inhibitors, S36
Histopathology, S10
History, S9
Hospitalized lung cancer patients, S46
HOXA9 methylation, S36
Human papilloma virus, S48









Immunohistochemistry, S41, S62, S85
IMRT, S89
Individual patient data, S68
Induced sputum, S49
Induction chemotherapy, S18, S50, S62, S84
Inflammatory markers, S74
Inoperable lung cancer, S76
Intensity modulated radiotherapy, S84, S88
International Staging Committee of the













Limited-stage small-cell lung cancer, S64
Lobectomy, S10
Locally advanced disease, S20, S62
Locally advanced NSCLC, S81, S88
Loss of HLA expression, S36
Lung, S29, S80, S83, S89, S97
Lung cancer, S10, S14, S23, S28, S29, S30,
S33, S36, S37, S39, S40, S43, S44, S46,
S47, S48, S49, S50, S53, S56, S61, S67,
S71, S74, S78, S80, S82, S91, S93, S95
Lung cancer staging, S14
Lung carcinoids, S47, S91





Lung tumors pathology classification, S10






Malignant pericardial effusion, S80
Malignant pleural mesothelioma, S84, S85, S86
Malnutrition, S79







Mesothelioma, S9, S24, S47, S84, S85, S86,
S87
Mesothelioma primary culture, S86
MET, S35
Meta-analysis, S20, S47, S68
Metastasis, S11





Molecular profiling, S33, S39
Molecular targeted therapy, S76
Molecular telomere, S50
Monototal, S38
Mortality in lung cancer, S46
mTOR, S96
















Non-small cell lung cancer (NSCLC), S9, S11,
S12, S16, S17, S18, S21, S23, S24, S26,
S27, S30, S32, S34, S35, S41, S42, S44,
S48, S50, S51, S52, S53, S55, S56, S57,
S59, S60, S62, S63, S64, S66, S69, S70,
S72, S73, S74, S75, S77, S78, S82, S83,
S88, S90, S91, S92, S94
NO synthase, S49
NSCLC IIIa/b, S13
















Patient selection, S22, S69
PCI, S55










Phase II, S72, S74, S77
Phase III trial, S65











Positron emission tomography, S53
Postoperative radiotherapy, S56
Postoperative surveillance, S51
Prediction of chemotherapy, S23
Predictive factors, S17,
Preneoplasia, S34, S35, S49
Pro-apoptotic function, S41
Prognosis, S23, S32, S48, S65, S69, S86
Journal of Thoracic Oncology • Volume 3, Number 4, Supplement 1, April 2008 Subject Index
Copyright © 2008 by the International Association for the Study of Lung Cancer S105
Prognostic factor, S17, S37, S57, S79
Proliferation, S85
Prophylactic irradiation, S21
Protein kinase C, S34












Radiographically occult lung cancer, S15
Radiosensitization, S94
Radiotherapy, S12, S13, S16, S20, S55, S64,
S81, S82, S89
Radiotherapy optimization, S31














Revision UICC 6, S14
RF ablation, S19
Ribonucleotide reductase M1 (RRM1), S16
RNA, S28
RNA processing machinery, S28





SCLC, S11, S25, S45, S54, S54
Screening, S23, S40, S44, S50, S73
Second-line, S26
Second line chemotherapy, S55
Second primary tumor, S52
Segmentectomy, S10, S20
Sense of guilt, S40
Sequential chemoradiotherapy, S62
Sequential chemotherapy, S58
Sequential treatment, S81, S84
Side effect, S21, S67, S71
Signaling, S28
Single nucleotide polymorphism, S86
Site of metastases, S69
Six minute walk, S74
Skeletal complications, S73
Small-cell lung cancer, S55, S95
Smoking, S27, S40, S66
SNPs, S37
Solitary focal abnormalities, S50
Solitary lung metastasis, S61
Soluble cytokeratins, S38
Soluble EGFR, S43
Somatic mutations, S32, S72
Splicing, S28
Sputum, S43
Squamous cell carcinoma, S34, S35
Stage I, S38
Stage III, S21, S63
Stage IIIB, S21
Stage III NSCLC, S52, S60, S81
Stage I non-small-cell lung cancer, S42
Stage IV, S69
Stage IV lung cancer, S69
Staging, S10, S14, S23, S52, S93
Staging NSCLC, S14
Stereotactic, S89




Sunitinib, S44, S69, S72, S77, S79, S97
Surgery, S12, S13, S17, S18, S56, S57, S61,
S93, S94









Targeted therapy, S25, S27, S28, S67, S78
Target volume, S53
TGF-1, S75
7th Edition of TNM, S14
Third-line therapy, S83, S95
Thoracoscopy, S92
Thromboembolic events, S97
Thymic cell carcinoma, S95





Timing of radiotherapy, S60








Tumor lysis syndrome, S88
Tumor markers, S38, S43
Tumor regression grade, S93
Tumor suppressor, S10, S29
Tyrosine kinase inhibitor, S27, S32, S35, S36,
S38, S69, S72, S77, S79
U
Unusual manifestation, S54
Urinary tumor marker, S44
V
Vascular endothelial growth factor (VEGF),
S30, S43, S44















Subject Index Journal of Thoracic Oncology • Volume 3, Number 4, Supplement 1, April 2008
Copyright © 2008 by the International Association for the Study of Lung CancerS106
